Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

bispecific antibodies

Immunotherapy highlights at IMS 2023: bispecific antibodies, CAR-T cells & unanswered questions 2:50
Immunotherapy highlights at IMS 2023: bispecific antibodies, CAR-T cells & unanswered questions
Heinz Ludwig • 27 Sep 2023
Unanswered questions regarding the sequencing of BCMA-targeting agents in multiple myeloma 4:45
Unanswered questions regarding the sequencing of BCMA-targeting agents in multiple myeloma
Mohamad Mohty • 29 Sep 2023
Determinants of response and resistance to T-cell engaging therapies in multiple myeloma 1:12
Determinants of response and resistance to T-cell engaging therapies in multiple myeloma
Shonali Midha • 29 Sep 2023
Talquetamab and teclistamab in triple-class refractory myeloma: important practical considerations 1:58
Talquetamab and teclistamab in triple-class refractory myeloma: important practical considerations
Karthik Ramasamy • 4 Oct 2023
WGS reveals sequential & persistent loss of BCMA and GPRC5D after bispecific antibodies in myeloma 1:47
WGS reveals sequential & persistent loss of BCMA and GPRC5D after bispecific antibodies in myeloma
Leo Rasche • 28 Sep 2023
MagnetisMM-3: correcting hypogammaglobulinemia & using Ig replacement therapy to reduce infections 3:47
MagnetisMM-3: correcting hypogammaglobulinemia & using Ig replacement therapy to reduce infections
Xavier Leleu • 29 Sep 2023
The value of bispecifics in myeloma & the importance of optimizing the sequencing of these agents 1:07
The value of bispecifics in myeloma & the importance of optimizing the sequencing of these agents
Azra Borogovac • 28 Sep 2023
The value of mosunetuzumab in R/R FL 1:46
The value of mosunetuzumab in R/R FL
Paolo Lopedote • 29 Sep 2023
The value of bispecifics in myeloma & the importance of optimally sequencing immunotherapies 1:27
The value of bispecifics in myeloma & the importance of optimally sequencing immunotherapies
Omar Nadeem • 28 Sep 2023
Disparities in access and practice patterns of BCMA-directed therapies in multiple myeloma 1:24
Disparities in access and practice patterns of BCMA-directed therapies in multiple myeloma
Shonali Midha • 29 Sep 2023
Risk of infection in patients with multiple myeloma treated with bispecific antibodies 1:22
Risk of infection in patients with multiple myeloma treated with bispecific antibodies
Samer Al Hadidi • 29 Sep 2023
Overcoming T-cell dysfunction 1:46
Overcoming T-cell dysfunction
Arnon Kater • 6 Oct 2023
The future of CLL treatment 0:53
The future of CLL treatment
Arnon Kater • 6 Oct 2023
Combining CAR-T with T cell-engaging bispecific antibodies to enhance efficacy in CLL murine models 1:08
Combining CAR-T with T cell-engaging bispecific antibodies to enhance efficacy in CLL murine models
Martina Seiffert • 8 Oct 2023
Treatment strategies under investigation for Richter’s transformation 0:40
Treatment strategies under investigation for Richter’s transformation
Erin Parry • 7 Oct 2023
Glofitamab in R/R DLBCL: updated safety and efficacy data 5:30
Glofitamab in R/R DLBCL: updated safety and efficacy data
Carmelo Carlo-Stella • 20 Oct 2023
The content of VJHemOnc is intended for healthcare professionals